EGFR and non-small cell lung carcinoma: Although there were possible shortcomings in the included studies, such as study design deficiency, inconsistency in clinical stage, various EGFR-TKIs included, non-uniform duration of EGFR-TKIs, inconsistent timing of medication and economic condition limiting and so on, the present study still provided an important and relative satisfactory clinical practice options for early-stage resected NSCLC patients harboring EGFR mutations.